JP5749014B2 - ポリプリントラクト改変レトロウイルスベクター - Google Patents

ポリプリントラクト改変レトロウイルスベクター Download PDF

Info

Publication number
JP5749014B2
JP5749014B2 JP2010538155A JP2010538155A JP5749014B2 JP 5749014 B2 JP5749014 B2 JP 5749014B2 JP 2010538155 A JP2010538155 A JP 2010538155A JP 2010538155 A JP2010538155 A JP 2010538155A JP 5749014 B2 JP5749014 B2 JP 5749014B2
Authority
JP
Japan
Prior art keywords
vector
nucleic acid
sequence
ltr
retroviral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010538155A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011505835A (ja
JP2011505835A5 (https=
Inventor
カフリ タル
カフリ タル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of JP2011505835A publication Critical patent/JP2011505835A/ja
Publication of JP2011505835A5 publication Critical patent/JP2011505835A5/ja
Application granted granted Critical
Publication of JP5749014B2 publication Critical patent/JP5749014B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Artificial Filaments (AREA)
  • Polyurethanes Or Polyureas (AREA)
JP2010538155A 2007-12-11 2008-12-11 ポリプリントラクト改変レトロウイルスベクター Expired - Fee Related JP5749014B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US711807P 2007-12-11 2007-12-11
US61/007,118 2007-12-11
PCT/US2008/086409 WO2009076524A2 (en) 2007-12-11 2008-12-11 Polypurine tract modified retroviral vectors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015013974A Division JP6001702B2 (ja) 2007-12-11 2015-01-28 ポリプリントラクト改変レトロウイルスベクター

Publications (3)

Publication Number Publication Date
JP2011505835A JP2011505835A (ja) 2011-03-03
JP2011505835A5 JP2011505835A5 (https=) 2012-02-02
JP5749014B2 true JP5749014B2 (ja) 2015-07-15

Family

ID=40756119

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010538155A Expired - Fee Related JP5749014B2 (ja) 2007-12-11 2008-12-11 ポリプリントラクト改変レトロウイルスベクター
JP2015013974A Expired - Fee Related JP6001702B2 (ja) 2007-12-11 2015-01-28 ポリプリントラクト改変レトロウイルスベクター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015013974A Expired - Fee Related JP6001702B2 (ja) 2007-12-11 2015-01-28 ポリプリントラクト改変レトロウイルスベクター

Country Status (16)

Country Link
US (2) US9796987B2 (https=)
EP (2) EP3342872A1 (https=)
JP (2) JP5749014B2 (https=)
CY (1) CY1119905T1 (https=)
DK (1) DK2222861T3 (https=)
ES (1) ES2664988T3 (https=)
HR (1) HRP20180184T1 (https=)
HU (1) HUE036103T2 (https=)
LT (1) LT2222861T (https=)
NO (1) NO2222861T3 (https=)
PL (1) PL2222861T3 (https=)
PT (1) PT2222861T (https=)
RS (1) RS56844B1 (https=)
SI (1) SI2222861T1 (https=)
TR (1) TR201802323T4 (https=)
WO (1) WO2009076524A2 (https=)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1885186B1 (en) 2005-06-01 2015-09-02 California Institute Of Technology Method of targeted gene delivery using viral vectors
US8329162B2 (en) 2006-07-21 2012-12-11 California Institute Of Technology Targeted gene delivery for dendritic cell vaccination
PL2222861T3 (pl) 2007-12-11 2018-04-30 The University Of North Carolina At Chapel Hill Wektory retrowirusowe ze zmodyfikowanym odcinkiem polipurynowym
RS53257B2 (sr) * 2009-07-24 2018-06-29 Immune Design Corp Lentiviralni vektori pseudotipizirani sa omotačem od glikobelančevine iz sindbis-virusa
WO2012112691A1 (en) 2011-02-15 2012-08-23 Immune Design Corp. Methods for enhancing immunogen specific immune responses by vectored vaccines
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
WO2013149167A1 (en) 2012-03-30 2013-10-03 Immune Design Corp. Lentiviral vector particles having improved transduction efficiency for cells expressing dc- sign
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
HRP20181102T1 (hr) 2012-05-16 2018-09-07 Immune Design Corp Cjepiva za hsv-2
ES2738582T3 (es) 2014-02-14 2020-01-23 Immune Design Corp Inmunoterapia del cáncer a través de combinación de inmunoestimulación local y sistémica
KR20170032373A (ko) 2014-07-15 2017-03-22 이뮨 디자인 코포레이션 Tlr4 작용제 보조제 및 렌티바이러스 벡터를 이용한 프라임-부스트 요법
KR101607282B1 (ko) 2014-12-18 2016-03-29 충남대학교산학협력단 유리형 산화환원조절단백-1 및 이를 함유하는 항염증 약학조성물
WO2016118780A1 (en) 2015-01-21 2016-07-28 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
WO2017066570A1 (en) * 2015-10-15 2017-04-20 The University Of North Carolina At Chapel Hill Methods and compositions for integration-defective lentiviral vectors
EP3365453A2 (en) 2015-10-22 2018-08-29 Juno Therapeutics GmbH Methods, kits, agents and apparatuses for transduction
WO2017083291A1 (en) 2015-11-09 2017-05-18 Immune Design Corp. Compositions comprising lentiviral vectors expressing il-12 and methods of use thereof
AU2016354102B2 (en) 2015-11-09 2022-05-12 Immune Design Corp. A retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids
JP2019509275A (ja) 2016-02-23 2019-04-04 イミューン デザイン コーポレイション マルチゲノムレトロウイルスベクター調製物ならびにそれらを産生および使用するための方法およびシステム
WO2017181152A2 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
MX2018012472A (es) 2016-04-15 2019-08-12 Alpine Immune Sciences Inc Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018022946A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
MA45783A (fr) 2016-07-29 2019-06-05 Juno Therapeutics Inc Procédés d'évaluation de la présence ou de l'absence d'un virus compétent pour la réplication
KR20190098747A (ko) 2016-12-05 2019-08-22 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료법을 위한 조작된 세포의 제조방법
SG11201907769XA (en) 2017-03-16 2019-09-27 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
KR20190141146A (ko) 2017-03-16 2019-12-23 알파인 이뮨 사이언시즈, 인코포레이티드 Pd-l2 변이체 면역조절 단백질 및 그의 용도
EP3596116B1 (en) 2017-03-16 2023-09-06 Alpine Immune Sciences, Inc. Pd-l1 variant immunomodulatory proteins and uses thereof
SG11202000606TA (en) 2017-07-29 2020-02-27 Juno Therapeutics Inc Reagents for expanding cells expressing recombinant receptors
KR20250016455A (ko) 2017-08-09 2025-02-03 주노 쎄러퓨티크스 인코퍼레이티드 유전자 조작된 세포 조성물 및 관련 조성물의 제조 방법
JP7749319B2 (ja) 2017-10-10 2025-10-06 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
BR112020007542A2 (pt) 2017-10-18 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras ligantes de icos variantes e composições e métodos relacionados
EP3704229B1 (en) 2017-11-01 2023-12-20 Juno Therapeutics, Inc. Process for producing a t cell composition
US12258580B2 (en) 2017-11-01 2025-03-25 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
MX2020005907A (es) 2017-12-08 2020-10-19 Juno Therapeutics Inc Formulacion de medio libre de suero para cultivar celulas y metodos de uso de la misma.
AU2019205273B2 (en) 2018-01-03 2024-04-04 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
JP2021511802A (ja) 2018-01-31 2021-05-13 ジュノー セラピューティクス インコーポレイテッド 複製可能ウイルスの存在または非存在を評価するための方法および試薬
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
EP3853247A2 (en) 2018-09-19 2021-07-28 Alpine Immune Sciences, Inc. Methods and uses of variant cd80 fusion proteins and related constructs
MA54078A (fr) 2018-11-01 2021-09-15 Juno Therapeutics Inc Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
IL283218B2 (en) 2018-11-16 2025-11-01 Juno Therapeutics Inc Dosing methods of engineered T cells for the treatment of malignant B cells
CA3120868A1 (en) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
PT3886875T (pt) 2018-11-30 2024-06-27 Juno Therapeutics Inc Métodos para tratamento utilizando terapia celular adotiva
CN113692285A (zh) 2018-11-30 2021-11-23 朱诺治疗学股份有限公司 在过继细胞疗法中给药和治疗b细胞恶性肿瘤的方法
MX2021012607A (es) 2019-04-17 2022-03-11 Alpine Immune Sciences Inc Metodos y usos de proteinas de fusion de ligando icos (icosl) variante.
CN114207136A (zh) 2019-06-07 2022-03-18 朱诺治疗学股份有限公司 自动化t细胞培养
KR20220034782A (ko) 2019-06-12 2022-03-18 주노 쎄러퓨티크스 인코퍼레이티드 세포 매개 세포 독성 요법 및 친생존 ｂｃｌ2 패밀리 단백질 억제제의 병용 요법
CN114555112A (zh) 2019-08-22 2022-05-27 朱诺治疗学股份有限公司 T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
JP2022554348A (ja) 2019-11-05 2022-12-28 ジュノー セラピューティクス インコーポレイテッド 治療用ｔ細胞組成物の属性を決定する方法
MX2022006715A (es) 2019-12-06 2022-09-23 Juno Therapeutics Inc Metodos relacionados con toxicidad y respuesta asociada con terapia celular para tratar neoplasias malignas de celulas b.
EP4093433A1 (en) 2020-01-24 2022-11-30 Juno Therapeutics, Inc. Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy
JP2023512209A (ja) 2020-01-28 2023-03-24 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞形質導入のための方法
JP2023522857A (ja) 2020-04-10 2023-06-01 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞成熟抗原を標的とするキメラ抗原受容体によって操作された細胞療法に関する方法および使用
EP4146684A2 (en) 2020-05-08 2023-03-15 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof
KR20230024283A (ko) 2020-05-13 2023-02-20 주노 쎄러퓨티크스 인코퍼레이티드 임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도
CA3197730A1 (en) 2020-10-15 2022-04-21 F. Hoffman-La Roche Ag Nucleic acid constructs for va rna transcription
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
CN117321200A (zh) 2021-03-22 2023-12-29 朱诺治疗学股份有限公司 评估病毒载体颗粒效力的方法
AU2022241654A1 (en) 2021-03-22 2023-09-28 Juno Therapeutics, Inc. Methods of determining potency of a therapeutic cell composition
CN117858719A (zh) 2021-03-29 2024-04-09 朱诺治疗学股份有限公司 使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法
US20240279310A1 (en) 2021-05-07 2024-08-22 Alpine Immune Sciences, Inc. Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
KR20240137075A (ko) 2022-01-28 2024-09-19 주노 쎄러퓨티크스 인코퍼레이티드 세포 조성물의 제조 방법
WO2023172883A1 (en) 2022-03-07 2023-09-14 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
EP4543923A1 (en) 2022-06-22 2025-04-30 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
KR20250099778A (ko) 2022-10-04 2025-07-02 알파인 이뮨 사이언시즈, 인코포레이티드 자가항체-매개 질환의 치료에 사용하기 위한 돌연변이된 taci-fc 융합 단백질
WO2024220588A1 (en) 2023-04-18 2024-10-24 Juno Therapeutics, Inc. Cytotoxicity assay for assessing potency of therapeutic cell compositions
WO2024226858A1 (en) 2023-04-26 2024-10-31 Juno Therapeutics, Inc. Methods for viral vector manufacturing
KR20260026101A (ko) 2023-05-23 2026-02-25 주노 쎄러퓨티크스 인코퍼레이티드 T 세포의 활성화 마커 및 t 세포 활성화를 평가하는 방법
WO2024263991A2 (en) * 2023-06-22 2024-12-26 Arc Research Institute Methods and compositions for integration deficient viral vectors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861161A (en) 1994-09-07 1999-01-19 Universite De Montreal Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions
JP2000503527A (ja) * 1995-11-28 2000-03-28 ザ ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン 条件付き複製ウイルスベクターおよびその用途
WO2001030965A2 (en) 1999-10-28 2001-05-03 The Board Of Trustees Of The Leland Stanford Junior University Methods of in vivo gene transfer using a sleeping beauty transposon system
US6673567B2 (en) 2000-03-23 2004-01-06 E. I. Du Pont De Nemours And Company Method of determination of gene function
US20030003565A1 (en) * 2000-11-27 2003-01-02 Dubensky Thomas W. Functional lentiviral vector from an MLV-based backbone
EP1534847B1 (en) 2002-09-03 2015-10-28 Oxford Biomedica (UK) Limited Retroviral vector and stable packaging cell lines
US7220578B2 (en) * 2002-11-27 2007-05-22 Tal Kafri Single LTR lentivirus vector
EP2055316A1 (en) * 2003-09-09 2009-05-06 VIRxSYS Corporation Lentivirus vector-based approaches for generating an immune response to HIV in humans
GB0325379D0 (en) * 2003-10-30 2003-12-03 Oxford Biomedica Ltd Vectors
US20060019393A1 (en) * 2003-12-04 2006-01-26 Cannon Paula M Minimal lentiviral vector system
US20070048285A1 (en) * 2005-08-24 2007-03-01 Christopher Baum Self-inactivating retroviral vector
EP1757703A3 (en) 2005-08-24 2007-12-05 Medizinische Hochschule Hannover Self-inactivating retroviral vector
PL2222861T3 (pl) 2007-12-11 2018-04-30 The University Of North Carolina At Chapel Hill Wektory retrowirusowe ze zmodyfikowanym odcinkiem polipurynowym

Also Published As

Publication number Publication date
JP6001702B2 (ja) 2016-10-05
WO2009076524A2 (en) 2009-06-18
US20180119170A1 (en) 2018-05-03
TR201802323T4 (tr) 2018-03-21
ES2664988T3 (es) 2018-04-24
CY1119905T1 (el) 2018-06-27
JP2015119715A (ja) 2015-07-02
US10017785B2 (en) 2018-07-10
US20100323403A1 (en) 2010-12-23
EP3342872A1 (en) 2018-07-04
LT2222861T (lt) 2018-03-26
HRP20180184T1 (hr) 2018-04-06
PL2222861T3 (pl) 2018-04-30
JP2011505835A (ja) 2011-03-03
HUE036103T2 (hu) 2018-06-28
NO2222861T3 (https=) 2018-05-05
EP2222861A2 (en) 2010-09-01
US9796987B2 (en) 2017-10-24
WO2009076524A3 (en) 2009-09-11
SI2222861T1 (en) 2018-04-30
PT2222861T (pt) 2018-02-16
EP2222861B1 (en) 2017-12-06
EP2222861A4 (en) 2011-12-28
DK2222861T3 (en) 2018-02-05
RS56844B1 (sr) 2018-04-30

Similar Documents

Publication Publication Date Title
JP5749014B2 (ja) ポリプリントラクト改変レトロウイルスベクター
US10184136B2 (en) Retroviral vectors
KR102091957B1 (ko) 레트로바이러스 생산을 위한 안정한 세포주
US8828718B2 (en) Gene transfer vectors comprising genetic insulator elements and methods to identify genetic insulator elements
ES2951857T3 (es) Vector retroviral
JP2019500030A (ja) レトロウイルス産生のための一時的トランスフェクション法
KR20220154734A (ko) 렌티바이러스 벡터
JP2023513303A (ja) レンチウイルスベクターの製造
Negre et al. Lentiviral vectors derived from simian immunodeficiency virus
CA2408786C (en) Retroviral vectors comprising an enhanced 3' transcription termination structure
US20250122528A1 (en) Lentiviral vector
US20230151388A1 (en) Modified vectors for production of retrovirus
van Heuvel Optimization of retroviral packaging cells for scale-up of vector production
WO2025213067A2 (en) Methods and compositions for increased expression of integration deficient viral vectors
Heuvel Optimization of retroviral packaging cells for scale-up of vector production

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140204

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140304

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140403

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140507

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150128

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150427

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150513

R150 Certificate of patent or registration of utility model

Ref document number: 5749014

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees